Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Traxoprodil"'
Publikováno v:
CNS Drugs
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca563228241db99a067d3977ff537199
https://europepmc.org/articles/PMC8201267/
https://europepmc.org/articles/PMC8201267/
Publikováno v:
Harvard Review of Psychiatry. 26:307-319
LEARNING OBJECTIVE After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic sys
Autor:
Kurex Sidik, Matthew Fronheiser, Yu-Wen Li, Adrienne Pena, Feng Luo, Linda J. Bristow, Patrick L Chow, Haiying Tang, Rick L. Pieschl, Daniel W. Kukral, Gabriel Tobon, Harold Malone, Wendy Hayes
Publikováno v:
Journal of Psychopharmacology. 32:146-155
Major depressive disorder is a leading cause of disability globally. Improvements in the efficacy of antidepressant therapy are needed as a high proportion (>40%) of individuals with major depressive disorder fail to respond adequately to current tre
Autor:
Ji Hoon Jeong, Hyoung-Chun Kim, Eun-Joo Shin, Seung-Yeol Nah, Naveen Sharma, Toshitaka Nabeshima, Bao-Chau Hoai Nguyen, Bao-Trong Nguyen, Ngoc Kim Cuong Tran, Dae-Joong Kim, David Lichtstein
Publikováno v:
Food and Chemical Toxicology. 158:112657
Dextromethorphan (DM) abuse produces mania-like symptoms in humans. ERK/Akt signaling activation involved in manic potential can be attenuated by the inhibition of ouabain-like cardiac steroids. In this study, increased phosphorylations of ERK/Akt an
Autor:
Carlos A. Zarate, Nicolas D. Iadarola, Elizabeth D. Ballard, Minkyung Park, Mark J. Niciu, Allison C. Nugent, Rodrigo Machado-Vieira, Níall Lally, Brittany A. Jaso, Erica M. Richards
Publikováno v:
Current Neuropharmacology
Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patie
Autor:
Venceslas Duveau, Niklas Schuelert, Boris Ferger, Henrike Raith, Corinne Roucard, Cornelia Dorner-Ciossek, Andrea Plano
Publikováno v:
Neuropharmacology. 171
Quantitative Electroencephalography (qEEG) and event-related potential (ERP) assessment have emerged as powerful tools to unravel translational biomarkers in preclinical and clinical psychiatric drug discovery trials. The aim of the present study was
Autor:
Robert Becker, Cornelia Dorner-Ciossek, David Schnell, Wolfgang Weber-Fahr, Alexander Sartorius, Lothar Kußmaul, Stefan Scheuerer, Natalia Gass, Bernhard Schmid
Publikováno v:
Psychopharmacology. 236(12)
The N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine is known to have not only a rapid antidepressant effect but also dissociative side effects. Traxoprodil and lanicemine, also NMDA antagonists, are candidate antidepressant drugs with fewer
Autor:
Guy A. Higgins, Fiona D. Zeeb, Julia Sevo, Leo B. Silenieks, Sandy Thevarkunnel, Cam MacMillan
Publikováno v:
Behavioural Brain Research. 311:1-14
NMDA GluN2B (NR2B) subtype selective antagonists are currently in clinical development for a variety of indications, including major depression. We previously reported the selective NMDA GluN2B antagonists Ro 63-1908 and traxoprodil, increase prematu
Autor:
Gerard Sanacora, Samuel T. Wilkinson
Mood disorders represent the largest cause of disability worldwide. The monoaminergic deficiency hypothesis, which has dominated the conceptual framework for researching the pathophysiology of mood disorders and the development of novel treatment str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df5dd1e7be27cd44ecca1f3a29c208b9
https://europepmc.org/articles/PMC6397075/
https://europepmc.org/articles/PMC6397075/
Autor:
Linda J. Bristow, Yu-Wen Li, Amy Newton, Trevor Wojcik, Praveena Baireddy, Yang Hong, Alda Fernandes, Yuan Tian, Rick L. Pieschl
Publikováno v:
European Journal of Pharmacology. 766:1-8
N-methyl-D-aspartate (NMDA) receptor antagonists, including open channel blockers and GluN2B receptor subtype selective antagonists, have been developed for the treatment of depression. The current study investigated effects of systemically administe